High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome

Clinical Lymphoma and Myeloma

Volumn 7, Issue 3, 2006, Pages 226-232

  Richardson, Stephen K ^a   Lin, Julie H ^a   Vittorio, Carmela C ^a   Kim, Ellen J ^a   Yoon, Jessica S ^a   Junkins Hopkins, Jacqueline ^a   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cutaneous T cell lymphoma; Extracorporeal photopheresis; Interferon ; Interferon

Indexed keywords

ALPHA INTERFERON; ANTILIPEMIC AGENT; BEXAROTENE; CARMUSTINE; CHLORMETHINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; LEVOTHYROXINE; PSORALEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOID;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL COUNT; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; GAMMA IRRADIATION; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; INFECTION; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PUVA; SEZARY SYNDROME; TREATMENT RESPONSE;

EID: 36649000815     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.063     Document Type: Article

References (50)

1. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Eng J Med 1999; 341:1817-1828.
2. Bunn PA Jr, Lamberg SI. Report on the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979; 63:725-728.
3. Zackheim HS, Amin S, Kashani-Sabet M, et al. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999; 40:418-425.
4. Kim YH, Chow S, Varghese A, et al. Clinical characteristics and longterm outcome of patients with generalized patch or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135:26-32.
5. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol 1999; 26:276-289
6. Rook AH, Vowels BR, Jaworsky C, et al. Immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cyrokine production by Sezary T-cells. Arch Dermatol 1993; 129:486-489.
7. Vowels BR, Cassin M, Vonderheid E, et al. Aberrant cytokine production by Sezary syndrome patients. Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99:90-94.
8. Peleman R, Wu J, Rargeas C, et al. Recombinant interleukin 4 suppresses the production of interferon gamma by mononuclear cells. J Exp Med 1989; 170:1751-1756.
9. D'Andrea A, Aste-Amezaga M, Valiante NM, et al. Interleukin-10 inhibits human lymphocyte IFN gamma-production by suppressing natural killer stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 1993; 178:1041-1048.
10. Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other varianis. J Am Acad Dermatol 1980; 2:89-106.
11. Martinez OM, Gibbos RS, Garovoy MR, et al. IL-4 inhibits IL-2 receptor expression and IL-2 dependent proliferation of human T cells. J Immunol 1990; 144:2211-2215.
12. Nagler A, Lanier LL, Phillips JH. The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J Immunol 1988; 141:2349-2351.
13. Kawakami Y, Custer MC, Rosenberg SA, et al. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J Immunol 1989; 142:3452-3461.
14. Coffman RL, Carty J. A T-cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol 1986; 136:949-954.
15. + human T cells. J Immunol 1991; 146:4209-4214.
16. Simon HU, Plotz SG, Dummer R, et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112-1120.
17. Sigurdsson V, Toonstra J, Bihari IC, et al. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An inimuno-histochemical study. J Cutan Pathol 2000; 27:429-435.
18. Yoo EK, Cassin MD, Lessin SR, et al. Complete molecular remission during biologic response modifier therapy for Sezary syndrome is associated with enhanced helper T type 1 cyotkine production and natural kill cell activity. J Am Acad Dermatol 2001; 45:208-216.
19. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46:95-106.
20. Rook AH, Berkson MH, Vowels BR, Extracorporeal photophoresis: principles and practice. In: Lim HW, Soter NA, eds. Clinical Photomedicine. New York, NY. Marcel Dekker; 1993:347-360.
21. Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis-fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tools (SWAT). Arch Dermatol 2002; 138:42-48.
22. Rook AH, Yoo EK, Grossman DJ, et al. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 1998; 10: 170-174.
23. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy. Arch Derm 2002; 138:1054-1060.
24. Knobler RM, Radaszkiewicz T. Treatment of cutaneous T-cell lymphoma. with a combination of low-dose interferon alpha 2b and retinoids. J Am Acad Dermatol 1991; 24:247-252.
25. Dreno, B, Celorier P. Litroux P. Roferon-A in combination with Tegason in cutaneous T-cell lymphomas. Acta Haematol 1993; 89:S28-S32.
26. Yoo EK, Rook AH, Elenitsas R, et al. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of action. J Invest Dermatol 1996; 107:235-242.
27. Osella-Abate S, Zaccagna A, Savoia P, et al. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy. J Am Acad Dermatol 2001; 44:40-47.
28. Vowels BF, Cassin M, Boufal MH, et al. Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 1992; 98:686-692.
29. Moor AC, Schmitt IM, Beijersbergen van Henegouwen GM, et al. Treatment with 8-MOP and UVA enhances MHC class 1 synthesis in RMA cells: preliminary results. J Photochem Photobiol B 1995; 29:193-198.
30. + circulating monocytes in patients with mycosis fungoides. Dermatology 1997; 194:107-110.
31. Bunn PA, Ihde DC, Foon KA. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphoma. Cancer 1986; 57:1689-1695.
32. Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB382IL-2 fusion toxin in cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 39:63-73.
33. Marolleau JP, Baccard M, Flageul B, et al. Higli-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995; 131:574-579.
34. Platsoucas CD, Fox FE, Oleszak E, et al. Regulation of natural killer cytotoxicity by recombinant alpha interferons: augmentation by IFN-alpha 7, an interferon similar to IFN-alpha. J Anticancer Res 1989; 9:849-858.
35. Fox FE, Nin Z, Lessin S, et al. Cytokine regulation of the growth of clonal malignant T-celts from patients with Sezary syndrome (abstract). J Invest Dermatol 1997; 108:552.
36. Gottlieb SL, Fox FE, Cassin M, et al. Interleukin 5 expression by peripheral blood mononuclear cells in Sezary syndrome correlates with peripheral eosinophilia and is suppressed by interferon alpha (abstract). J Invest Dermatol 1995; 104:683.
37. Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis hingoides). Arch Dermatol 1987; 123:201-204.
38. Kessler JF, Meyskens FL Jr, Levine N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet 1983; 1:1345-1347.
39. Fox FE, Kubin M, Cassin M, et al. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 1999; 19:407-415.
40. Chen G, Kang K, Kang S, et al. Differential induction of IL12 p40 and IL-10 mRNA in human Lagerhans cells and keratinocytes by in vivo occlusion, vehicle and all-trans retinoic acid. J Cutan Med Surg 1996; 1:74-80.
41. Meunier L, Bohjanen K, Voorhees JJ, et al. Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and cd11c, a beta 2 integrin critically involved in T-cell activation. J Invest Dermatol 1994; 103:775-779.
42. Dennert G, Lotan R. Effects of retinoic acid on the immune system: stimulation of T killer cell induction. Eur J Immunol 1978; 8:23-29.
43. Goldfarb RH, Herberman R-B. Natural killer cell reactivity: regulatory interactions among phorbol ester, interferon, cholera toxin, and retinoic acid. J Immunol 1981; 126:2129-2135.
44. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Bexarotene Study Group. Arch Dermatol 2001; 137:581-593.
45. Budgin JB, Richardson SK, Newton SB, et al. Biological effects of hexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005; 141:315-321.
46. Rowe JM, Anderson JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. Blood 1995; 86:457-462.
47. Honkoop AH, Luykx-de Bakker SA, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 1999; 4:106-111.
48. Bouwhuis SA, Markovic SN, McEvoy MT et al. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sezary syndrome. Mayo Clin Proc 2002; 77:197-200.
49. Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996; 132:1309-1313.
50. Kim YH, Bishop K, Varghese A, et al. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 1995; 131:1003-1008.